SENS - Senseonics Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.10
+0.14 (+4.73%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.96
Open2.97
Bid3.10 x 1000
Ask0.00 x 1000
Day's Range2.81 - 3.19
52 Week Range2.41 - 5.29
Volume3,743,656
Avg. Volume2,017,225
Market Cap548.235M
Beta (3Y Monthly)0.41
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Report: Exploring Fundamental Drivers Behind Sterling Construction, Tredegar, j2 Global, Medical Transcription Billing, Concert Pharmaceuticals, and Senseonics — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of SENS earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Senseonics Holdings Inc Earnings Call

  • Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
    Zacks9 days ago

    Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of 6.67% and 6.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press9 days ago

    Senseonics: 3Q Earnings Snapshot

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 18 cents. Losses, adjusted for non-recurring costs, were 14 cents per share. The results beat Wall Street expectations. ...

  • Business Wire9 days ago

    Senseonics Holdings, Inc. Reports Third Quarter 2018 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the third quarter ended September 30, 2018.

  • Business Wire11 days ago

    Senseonics Announces FDA Approval to Expand Eversense® CGM Certification to Nurse Practitioners and Physician Assistants

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has received FDA approval for qualified health care providers to be trained and certified to provide patients with the highly accurate sensor that lasts up to three months. Previously, the sensor insertion and removal procedure could only be performed by trained physicians.

  • Earnings Preview: Senseonics Holdings (SENS) Q3 Earnings Expected to Decline
    Zacks17 days ago

    Earnings Preview: Senseonics Holdings (SENS) Q3 Earnings Expected to Decline

    Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Newsfile23 days ago

    CSE New Listing - Sensor Technologies Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 26, 2018) -  Sensor Technologies (CSE: SENS) is one of the latest new listing on the Canadian Securities Exchange, having previously traded on the TSX Venture Exchange as Mooncor Oil and Gas under the symbol "MOO". Sensor Technologies and Fox-Tek Canada entered into an amalgamation agreement in June 2018 whereby the two companies will amalgamate and continue under the name Sensor Technologies Inc.InvestmentPitch Media has produced a "video" ...

  • Newsfile24 days ago

    Sensor Receives $194,587 in New Contracts

    Toronto, Ontario--(Newsfile Corp. - October 25, 2018) - Sensor Technologies Corp. (CSE: SENS) (formerly Mooncor Oil & Gas Corp.) (the "Corporation"), a developer and marketer of patented non-intrusive sensing systems, is pleased to announce that it has been awarded three (3) contracts, two (2) of which are for a complete leak detection systems to monitor infrastructure for one of North America's largest pipeline companies and the third contract for phase two (phase one proof-of-concept ...

  • Newsfile25 days ago

    Sensor to Commence Trading on the Canadian Securities Exchange

    Toronto, Ontario--(Newsfile Corp. - October 24, 2018) - Sensor Technologies Corp. (formerly Mooncor Oil & Gas Corp.) (CSE: SENS) (the "Corporation") is pleased to announce that on the opening of the market on October 24, 2018, the Corporation's common shares will commence trading through the facilities of the Canadian Securities Exchange ("CSE"). The common shares will trade under the symbol "SENS". The Corporation is also pleased to announce that it has completed the acquisition ...

  • Why Senseonics Holdings Inc. Is Soaring Today
    Motley Fool26 days ago

    Why Senseonics Holdings Inc. Is Soaring Today

    Shares popped after the company announced a favorable reimbursement agreement.

  • Business Wire26 days ago

    Senseonics Announces Aetna’s Positive Coverage Decision for Eversense

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that Aetna, the third largest commercial health plan provider in the United States, is providing coverage for Eversense, effective immediately. Aetna’s plan provides coverage for approximately 22 million lives in the United States. This recent coverage decision adds to the growing body of payers processing claims and paying for Eversense in the U.S.

  • GlobeNewswirelast month

    New Research Coverage Highlights QuinStreet, Senseonics, Ring Energy, Blue Apron, Second Sight Medical Products, and Real Goods Solar — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wirelast month

    Senseonics Holdings, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 8, 2018 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its third quarter 2018 financial results after market close on Thursday, November 8, 2018. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. (NYSE American: SENS) is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Simply Wall St.2 months ago

    Do You Know Who Else Invests In Senseonics Holdings Inc (NYSEMKT:SENS)?

    The big shareholder groups in Senseonics Holdings Inc (NYSEMKT:SENS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...

  • Are Options Traders Betting on a Big Move in Senseonics Holdings (SENS) Stock?
    Zacks2 months ago

    Are Options Traders Betting on a Big Move in Senseonics Holdings (SENS) Stock?

    Investors need to pay close attention to Senseonics Holdings (SENS) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SENS earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 Senseonics Holdings Inc Earnings Call

  • Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of -23.08% and -7.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Senseonics: 2Q Earnings Snapshot

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 23 cents. Losses, adjusted for non-recurring costs, were 16 cents per share. The medical technology company posted revenue ...

  • Business Wire3 months ago

    Senseonics Holdings, Inc. Reports Second Quarter 2018 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the second quarter ended June 30, 2018.

  • ACCESSWIRE3 months ago

    Senseonics Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Senseonics Holdings, Inc. (NYSE MKT: SENS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern ...

  • Business Wire3 months ago

    Senseonics Begins U.S. Commercialization of Eversense Continuous Glucose Monitoring System With First Shipment, First Users and First Policy Coverage

    Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that the Eversense® CGM System is now available at trained clinics across the U.S. and physicians have begun sensor placements with patients. Concurrently, the company reported that its first commercial payer, Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey, has added coverage of the Eversense System to its Medical Policy.

  • Investopedia4 months ago

    Penny Stocks to Watch for August 2018

    Penny stock pickers booked modest returns in these tough conditions, while trend followers and dart throwers took losses. The July penny stock list generated mixed returns, with precious metals and biotech headwinds limiting gains while a mid-month crude oil reversal undermined small energy plays.

  • Business Wire4 months ago

    Senseonics to Participate in the Canaccord Genuity Growth Conference

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ Eversense System is a long-term, implantable device, which includes a small sensor, smart transmitter and mobile application.

  • Business Wire4 months ago

    Senseonics Holdings, Inc. Schedules Second Quarter 2018 Earnings Release and Conference Call for August 8, 2018 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced that it plans to release its second quarter 2018 financial results after market close on Wednesday, August 8, 2018. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease.